Ipamorelin 5mg
Selective pentapeptide GH secretagogue acting on the GHS-R1a receptor to trigger somatotropic release without elevating cortisol or prolactin.
Mechanism
Acts as a selective agonist at the pituitary GHS-R1a ghrelin receptor to stimulate pulsatile growth hormone secretion without driving cortisol or prolactin production.
Dosing
Standard laboratory protocols initiate investigation at 100 mcg daily, frequently titrated up to 250 mcg across multi-week evaluation phases.
Reconstitution
Adding 3.0 mL of bacteriostatic water to a 5 mg vial yields an approximate working concentration of 1.67 mg/mL (1,670 mcg/mL).
Storage
Store the dry lyophilized powder between 2–8 °C or frozen at -20 °C, and maintain the reconstituted liquid refrigerated at 2–8 °C away from light without freezing.
Mix & measure Ipamorelin 5mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure Ipamorelin 5mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 50.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (1× daily) | 6 units (0.06 mL) |
| Weeks 3–4 | 150 mcg (1× daily) | 9 units (0.09 mL) |
| Weeks 5–8 | 200 mcg (1× daily) | 12 units (0.12 mL) |
| Weeks 9–12 | 250 mcg (1× daily) | 15 units (0.15 mL) |
Reconstitution Steps
- 1
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
- 2
Release it slowly down the vial's inner wall to limit foaming.
- 3
Swirl or roll gently until fully dissolved — don't shake.
- 4
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Supplies Needed
Peptide Vial
Lyophilized Ipamorelin 5 mg vial for reconstitution.
Insulin Syringes (U-100)
Fine-gauge U-100 syringes for accurate micro-volume draws.
Bacteriostatic Water
3.0 mL sterile diluent containing 0.9% benzyl alcohol.
Alcohol Swabs
Used for sanitizing the vial rubber septum and local injection sites.
Why researchers study it
GH & IGF-1 support
Body composition & lean mass
Fat metabolism / lipolysis
GI motility & recovery
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
Ipamorelin is an engineered synthetic pentapeptide recognized as a highly selective agonist of the growth hormone secretagogue receptor (GHS-R1a). In scientific investigations, it mimics the action of ghrelin by binding directly to pituitary receptors, prompting a focused, pulsatile release of endogenous growth hormone. Unlike older secretagogues within the same broad class, its signaling pathway demonstrates negligible activation of adrenocorticotropic hormone (ACTH), cortisol, or prolactin secretion under standard research concentrations. Preclinical research primarily focuses on understanding somatotropic signaling, lipid mobilization, and systemic body composition changes mediated by pulsatile GH surges. While explored in early-phase human trials for gastrointestinal motility indications like postoperative ileus, clinical endpoints were not achieved, and the molecule remains strictly an investigational tool rather than an approved therapeutic agent.
References
- 1.Raun et al., Bioorganic & Medicinal Chemistry Letters, 1998 — Ipamorelin: the first selective growth-hormone secretagogue, characterizing GHS-R1a binding and GH release
- 2.ClinicalTrials.gov, Phase II trial, 2014 — Phase II trial of Ipamorelin for postoperative ileus
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allMOTS-c 10mg
Mitochondrial-derived 16-amino acid peptide that activates AMPK and regulates cellular energy metabolism and insulin sensitivity.
View ProtocolTesofensine 0.5mg
An investigational oral triple monoamine reuptake inhibitor researched in Phase II clinical trials for weight regulation and appetite suppression.
View ProtocolSemaglutide 5mg
Synthetic GLP-1 receptor agonist studied for glycemic regulation, delayed gastric motility, and metabolic weight management pathways.
View Protocol